Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Antibody and T-cell responses to COVID-19 vaccination in patients with MPNs

Gabriela Hobbs • 11 Dec 2021
ASH 2021
Chronic Myeloid Leukemia Essential Thrombocythemia Leukemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Ruxolitinib

In this video, Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, highlights some findings from a study which aimed to investigate the response of myeloproliferative neoplasm (MPN) patients to COVID-19 vaccination. Dr Hobbs first explains how patient samples were collected, and then discusses some of the positive results that were obtained, comparing both serologic and T-cell responses to vaccination in different patient cohorts. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

More from Gabriela Hobbs

1:20
Future directions in chronic phase CML treatment
Gabriela Hobbs • 11 Dec 2021
1:51
Checkpoint inhibition in the treatment of MPNs
Gabriela Hobbs • 11 Dec 2021
0:58
Outcomes of MPN patients versus non-MPN patients hospitalized for COVID-19
Gabriela Hobbs • 11 Dec 2021
2:36
Phase II study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis
Gabriela Hobbs • 11 Dec 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals